Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Haematologica
|
September 12, 2000
Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring
G Meloni, A Proia, F Mauro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study
M Martelli, M Vignetti, P L Zinzani, et al.
Annals of Hematology
|
April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
R Willemze, S Suciu, P Muus, et al.
Leukemia
|
October 31, 2003
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))
A Palumbo, S Bringhen, A Bertola, et al.
British Journal of Cancer
|
August 9, 2012
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
F Efficace, M Baccarani, G Rosti, et al.
Haematologica
|
September 8, 1999
Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo
I Majolino, M Vignetti, G Meloni, et al.
Leukemia
|
August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori, S Suciu, R Stasi, et al.
Leukemia
|
May 24, 2003
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
F Mandelli, R Latagliata, G Avvisati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2005
Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials
L Pagano, A Pulsoni, M Vignetti, et al.
Bone Marrow Transplantation
|
November 18, 2014
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
M Hengeveld, S Suciu, Y Chelgoum, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Haematologica
|
September 12, 2000
Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring
G Meloni, A Proia, F Mauro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study
M Martelli, M Vignetti, P L Zinzani, et al.
Annals of Hematology
|
April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
R Willemze, S Suciu, P Muus, et al.
Leukemia
|
October 31, 2003
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))
A Palumbo, S Bringhen, A Bertola, et al.
British Journal of Cancer
|
August 9, 2012
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
F Efficace, M Baccarani, G Rosti, et al.
Haematologica
|
September 8, 1999
Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo
I Majolino, M Vignetti, G Meloni, et al.
Leukemia
|
August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori, S Suciu, R Stasi, et al.
Leukemia
|
May 24, 2003
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
F Mandelli, R Latagliata, G Avvisati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2005
Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials
L Pagano, A Pulsoni, M Vignetti, et al.
Bone Marrow Transplantation
|
November 18, 2014
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
M Hengeveld, S Suciu, Y Chelgoum, et al.
Page
of 5